Loading...
Over the past decade, multiple clinical trials have demonstrated clinically meaningful improvements in overall survival (OS) for most men with newly diagnosed metastatic prostate cancer by “intensifying” androgen deprivation therapy (ADT) with the addition of drugs such as docetaxel, abiraterone, enzalutamide, and apalutamide. Now, in the phase 3, industry-supported European PEACE-1 trial, investigators evaluated further intensification — i.e., triplet therapy — and the role of local radiotherapy.
In the open-label trial, 1173 men with de novo metastatic prostate cancer were randomized to receive standard of care (SOC; ADT) alone, SOC plus radiotherapy, SOC plus abiraterone, or SOC plus radiotherapy plus abiraterone. The trial was amended af…